These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10926446)

  • 1. Evaluation of gemifloxacin (SB-265805, LB20304a): in vitro activity against over 6000 gram-positive pathogens from diverse geographic areas.
    Jones RN; Pfaller MA; Erwin ME
    Int J Antimicrob Agents; 2000 Aug; 15(3):227-30. PubMed ID: 10926446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
    Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
    Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines.
    Johnson DM; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Feb; 33(2):87-91. PubMed ID: 10091031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
    Jones RN; Beach ML; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):247-52. PubMed ID: 9884844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
    Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
    Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
    Cormican MG; Jones RN
    Antimicrob Agents Chemother; 1997 Jan; 41(1):204-11. PubMed ID: 8980783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
    Oh JI; Paek KS; Ahn MJ; Kim MY; Hong CY; Kim IC; Kwak JH
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1564-8. PubMed ID: 8726042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria.
    Sefton AM; Maskell JP; Rafay AM; Whiley A; Williams JD
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():57-62. PubMed ID: 9222071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of gemifloxacin compared with other antimicrobial agents against recent clinical isolates of streptococci.
    Ieven M; Goossens W; De Wit S; Goossens H
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():51-3. PubMed ID: 10824033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina.
    Lopez H; Stepanik D; Vilches V; Scarano S; Sarachian B; Mikaelian G; Finlay J; Sucari A
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):187-92. PubMed ID: 11576792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vitro activity of trovafloxacin against gram-positive and gram-negative organisms with quinolones and beta-lactam antimicrobial agents.
    Dembry LM; Roberts JC; Schock KD; Marino SP; Farrel PA; Andriole VT
    Diagn Microbiol Infect Dis; 1998 May; 31(1):301-11. PubMed ID: 9597391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of gemifloxacin.
    King A; May J; French G; Phillips I
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():1-12. PubMed ID: 10824026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the in vitro activity of gemifloxacin against gram-positive and gram-negative anaerobic pathogens.
    Goldstein EJ
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():55-65. PubMed ID: 10824034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Kutlin A; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2806-7. PubMed ID: 10543770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae.
    Kerawala M; Ambler JE; Lee PY; Drabu YJ
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):271-5. PubMed ID: 11399019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.